PMVP PMVP
Company Profile ↓Company Overview
PMVP (PMVP) is a publicly traded company listed on with a market capitalization of $62.40M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -18.75% |
| 6 Months: | +8.33% |
| 3 Months: | -14.60% |
| 1 Month: | -5.65% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.32 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 35.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 21.56M | 22.88M | 22.52M | 19.24M | 19.02M |
| Operating Income | - | - | -6.44M | -7.65M | -8.09M | -8.70M | -11.67M | -13.05M | -15.10M | -18.62M | -17.89M | -19.38M | -21.48M | -20.12M | -19.63M | -18.22M | -20.17M | -21.89M | -21.56M | -22.88M | -22.52M | -19.24M | -19.02M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -21.53M | -22.85M | -22.49M | -19.21M | -18.98M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -19.63M | -21.20M | -21.07M | -18.01M | -18.04M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.20M | 5.00K | -6.00K | 26.00K | 0 |
| Net Income | -6.00M | -6.13M | -6.17M | -7.25M | -7.97M | -8.76M | -11.60M | -12.87M | -15.01M | -18.43M | -17.31M | -18.23M | -19.13M | -17.44M | -16.64M | -15.27M | -1.21M | -19.23M | -17.44M | -21.21M | -21.06M | -18.04M | -18.04M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.33 | -0.41 | -0.38 | -0.40 | -0.42 | -0.38 | -0.34 | -0.30 | -0.02 | -0.37 | -0.34 | -0.41 | -0.40 | - | -0.34 |
| R&D Expense | - | - | 4.89M | 5.96M | 5.80M | 5.99M | 7.50M | 7.66M | 9.16M | 11.84M | 11.46M | 13.67M | 15.07M | 13.84M | 13.59M | 13.19M | 14.63M | 16.95M | 17.44M | 18.40M | 18.21M | - | 15.33M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 77.04M | 80.13M | 85.45M | 86.21M |
| Operating Income | -18.89M | -26.64M | -34.94M | -58.29M | -77.04M | -80.13M | -85.45M | -86.21M |
| EBITDA | - | - | - | - | -76.72M | -78.88M | -84.30M | -86.07M |
| Interest Expense | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | -73.33M | -68.96M | -74.81M | -79.91M |
| Tax Provision | - | - | - | - | -9.00K | 2.00K | -16.10M | -2.17M |
| Net Income | -17.54M | -25.35M | -34.44M | -57.85M | -73.32M | -68.96M | -58.71M | -77.74M |
| Diluted EPS | - | - | -2.40 | -1.28 | -1.61 | -1.44 | -1.14 | -1.48 |
| R&D Expense | 13.85M | 20.76M | 23.93M | 36.49M | 51.99M | 55.88M | 58.53M | 69.88M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 103.03M | 365.53M | - | 270.31M | 252.15M | 191.29M | 116.56M |
| Current Assets | - | - | - | - | - | 247.01M | 207.41M | 175.66M | 115.23M |
| Cash & Equivalents | - | - | 73.28M | 361.42M | - | 108.30M | 37.71M | 40.88M | 37.98M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 4.57M | 6.41M | - | 24.28M | 26.46M | 15.21M | 11.85M |
| Current Liabilities | - | - | 4.52M | 6.41M | - | 10.83M | 14.03M | 14.37M | 11.41M |
| Long Term Debt | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | 13.98M | 13.29M | 1.19M | 838.00K |
| Total Equity | -29.73M | -46.14M | -70.47M | 359.12M | - | 246.03M | 225.69M | 176.08M | 104.71M |
| Shares Outstanding | - | - | - | - | - | 45.77M | 51.45M | 51.94M | 53.33M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -15.18M | -22.07M | -32.74M | - | -63.76M | -55.66M | -51.28M | -73.58M |
| Investing Cash Flow | 21.69M | 3.23M | 27.91M | - | -1.37M | -50.55M | 53.35M | 70.17M |
| Financing Cash Flow | - | 61.80M | 292.97M | - | 958.00K | 35.58M | 313.00K | 505.00K |
| Capital Expenditure | -452.00K | -109.00K | -148.00K | - | -7.98M | -962.00K | -655.00K | -29.00K |
| Free Cash Flow | -15.63M | -22.17M | -32.89M | - | -71.74M | -56.62M | -51.94M | -73.61M |
| Net Change in Cash | - | - | - | - | -64.17M | -70.62M | 2.38M | -2.90M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - |
| ROE % | 38.0% | 36.0% | -9.6% | - | -29.8% | -30.6% | -33.3% | -74.2% |
| ROCE % | - | -27.0% | -9.7% | - | -29.7% | -33.7% | -48.3% | -82.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PMVP
PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PMV Pharmaceuticals (PMVP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversa…
Why PMV Pharmaceuticals, Inc. (PMVP) Faces Funding Concerns Despite Positive Trial Activity
We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) is among the most popular penny stocks on Robinhood. TheFly reported on May 13 that Oppenheimer reduced its pr…
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Staar Surgical (NASDAQ:STAA) shares rose 15.3% to $33.9 during Wednesday's after-market session. The company's market cap stands at $1.3 billion. As per the press release, Q1 earnings came out today. Precision Optics Corp (NASDAQ:PO…
PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights
Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancerNew England Journal of Medicine published first-in-human rezatapopt data showing selective reactivati…
PMV Pharmaceuticals Announces Board Chair Transition
Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new ChairPRINCETON, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP)…
Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
PMVP — Frequently Asked Questions
What is the current share price of PMVP?
As of 2026-08-05 17:25 PDT, PMVP trades at $1.17 on NASDAQ/NYSE. Its 52-week range is $1.02 to $1.80.
What is the market capitalisation of PMVP?
PMVP has a market capitalisation of $62.40M on NASDAQ/NYSE.
What is the P/E ratio of PMVP?
PMVP trades at a trailing price-to-earnings (P/E) ratio of -0.79. Its price-to-book (P/B) ratio is 0.60.
What is the return on equity (ROE) of PMVP?
PMVP has a return on equity (ROE) of -74.24%. Its return on capital employed (ROCE) is -81.99%.
Is PMVP a good stock to buy?
This page provides a data-driven analysis of PMVP, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.